{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T14:24:11Z","timestamp":1788531851214,"version":"build-2803163510"},"reference-count":39,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001738","name":"Israeli Ministry of Innovation, Science and Technology","doi-asserted-by":"publisher","award":["0006031"],"award-info":[{"award-number":["0006031"]}],"id":[{"id":"10.13039\/501100001738","id-type":"DOI","asserted-by":"publisher"}]},{"award":["0006031"],"award-info":[{"award-number":["0006031"]}],"id":[{"id":"https:\/\/ror.org\/02heb2n75","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Inflammatory bowel disease (IBD), including Crohn\u2019s disease and ulcerative colitis, is a chronic disorder characterized by persistent intestinal inflammation. Although corticosteroids such as prednisolone effectively control disease symptoms, prolonged treatment is associated with severe side effects, including immune suppression and metabolic disturbances. To enable site-specific drug delivery, four phospholipid\u2013linker\u2013prednisolone conjugates were designed and synthesized as prodrugs targeting the overexpression of phospholipase A2 (PLA2) in inflamed intestinal tissues. The conjugates were prepared using a reversed synthetic strategy, in which the phospholipid\u2013linker scaffold was assembled before drug coupling. The effect of spacer length on molecular conformation and predicted structural determinants of enzymatic activation was investigated through in silico analysis. Molecular docking simulations performed using the AutoDock Vina v1.2.7 framework, followed by structural and distance analysis in UCSF Chimera and 50 ns molecular dynamics simulations in GROMACS, suggested that linker length may influence ligand orientation, conformational orientation, ligand stability, and the spatial positioning of the ester bond relative to the catalytic histidine residue within the PLA2 active site. Among the two conjugates examined in detail by molecular dynamics, C6 maintained comparatively lower ligand mobility and a shorter average distance to the catalytic residue His47 than C12. These computational findings provide structural insights that may guide the future design and optimization of phospholipid-based corticosteroid prodrugs for targeted IBD therapy.<\/jats:p>","DOI":"10.3390\/molecules31173057","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:05:26Z","timestamp":1788224726000},"page":"3057","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phospholipid\u2013Prednisolone Conjugates for Targeted IBD Therapy: Structural Design, Synthetic Approaches, Optimization, and Computational Evaluation"],"prefix":"10.3390","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4904-7427","authenticated-orcid":false,"given":"Sapir","family":"Ifrah","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology, School of Pharmacy, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Adi","family":"Jabarin","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, School of Pharmacy, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"software","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4962-4938","authenticated-orcid":false,"given":"Ludmila","family":"Yarmolinsky","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, School of Pharmacy, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1894-6956","authenticated-orcid":false,"given":"Keren","family":"Cohen-Hagai","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, Meir Medical Center, Kfar Saba 4428164, Israel"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Mordechai","family":"Deutsch","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, Meir Medical Center, Kfar Saba 4428164, Israel"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"funding-acquisition","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3498-3514","authenticated-orcid":false,"given":"Arik","family":"Dahan","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, School of Pharmacy, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"funding-acquisition","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7551-5488","authenticated-orcid":false,"given":"Shimon","family":"Ben-Shabat","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, School of Pharmacy, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"funding-acquisition","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMra0804647","article-title":"Mechanisms of disease","volume":"361","author":"Abraham","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990\u20132017: A systematic analysis for the Global Burden of Disease Study 2017","volume":"5","author":"Alatab","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(07)60750-8","article-title":"Inflammatory bowel disease: Cause and immunobiology","volume":"369","author":"Baumgart","year":"2007","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"111436","DOI":"10.1016\/j.fct.2020.111436","article-title":"Luteolin alleviates ochratoxin A induced oxidative stress by regulating Nrf2 and HIF-1\u03b1 pathways in NRK-52E rat kidney cells","volume":"141","author":"Liu","year":"2020","journal-title":"Food Chem. Toxicol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41522-025-00830-7","article-title":"TNF-\u03b1 modulation by rice bran peptides: Implications for gut microbiota stability and cognitive health in aging","volume":"11","author":"Mu","year":"2025","journal-title":"npj Biofilms Microbiomes"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/CM9.0000000000003542","article-title":"Epidemiology, pathogenesis, diagnosis, and treatment of inflammatory bowel disease: Insights from the past two years","volume":"138","author":"Wan","year":"2025","journal-title":"Chin. Med. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.4103\/0976-500X.120975","article-title":"Corticosteroid-related central nervous system side effects","volume":"4","author":"Ciriaco","year":"2013","journal-title":"J. Pharmacol. Pharmacother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.gtc.2004.02.002","article-title":"Treatment of inflammatory bowel disease with corticosteroids","volume":"33","author":"Katz","year":"2004","journal-title":"Gastroenterol. Clin."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/ecco-jcc\/jjaa053","article-title":"The historical role and contemporary use of corticosteroids in inflammatory bowel disease","volume":"14","author":"Dorrington","year":"2020","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/sj.bjp.0706736","article-title":"How corticosteroids control inflammation: Quintiles Prize Lecture 2005","volume":"148","author":"Barnes","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.abd.2023.05.005","article-title":"Side effects of chronic systemic glucocorticoid therapy: What dermatologists should know","volume":"99","author":"Tavares","year":"2024","journal-title":"An. Bras. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1586\/eci.10.30","article-title":"Drug targeting strategies for the treatment of inflammatory bowel disease: A mechanistic update","volume":"6","author":"Dahan","year":"2010","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1517\/17425247.2012.697055","article-title":"Targeted prodrugs in oral drug delivery: The modern molecular biopharmaceutical approach","volume":"9","author":"Dahan","year":"2012","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1517\/17425247.2.3.451","article-title":"Novel drug delivery strategies for the treatment of inflammatory bowel disease","volume":"2","author":"Kesisoglou","year":"2005","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1208\/s12249-015-0350-9","article-title":"Colon-targeted oral drug delivery systems: Design trends and approaches","volume":"16","author":"Amidon","year":"2015","journal-title":"AAPS PharmSciTech"},{"key":"ref_17","first-page":"33","article-title":"Pharmaceutical approaches to colon targeted drug delivery systems","volume":"6","author":"Chourasia","year":"2003","journal-title":"J. Pharm. Pharm. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000341947","article-title":"Topical therapies in inflammatory bowel disease","volume":"86","author":"Frei","year":"2012","journal-title":"Digestion"},{"key":"ref_19","first-page":"183","article-title":"Intraluminal pH of the human gastrointestinal tract","volume":"46","author":"Fallingborg","year":"1999","journal-title":"Dan. Med. Bull."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3390\/molecules13020452","article-title":"Application of Prodrugs to Inflammatory Diseases of the Gut","volume":"13","author":"Oz","year":"2008","journal-title":"Molecules"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/gut.40.1.95","article-title":"Gene expression of group II phospholipase A2 in intestine in ulcerative colitis","volume":"40","author":"Nurmi","year":"1997","journal-title":"Gut"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1572-0241.1999.00941.x","article-title":"Gene expression of group II phospholipase A2 in intestine in Crohn\u2019s disease","volume":"94","author":"Nurmi","year":"1999","journal-title":"Off. J. Am. Coll. Gastroenterol. ACG"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.1194\/jlr.R800033-JLR200","article-title":"Phospholipase A2 structure\/function, mechanism, and signaling1","volume":"50","author":"Burke","year":"2009","journal-title":"J. Lipid Res."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Markovic, M., Abramov-Harpaz, K., Regev, C., Ben-Shabat, S., Aponick, A., Zimmermann, E.M., Miller, Y., and Dahan, A. (2022). Prodrug-Based Targeting Approach for Inflammatory Bowel Diseases Therapy: Mechanistic Study of Phospho-lipid-Linker-Cyclosporine PLA(2)-Mediated Activation. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23052673"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1080\/07391102.2023.2205949","article-title":"Antimalarial potential, LC\u2013MS secondary metabolite profiling and computational studies of Zingiber officinale","volume":"42","author":"Faloye","year":"2023","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1080\/07391102.2023.2291174","article-title":"Investigating the multitargeted anti-diabetic potential of cucurbitane-type triterpenoid from Momordica char-antia: An LC-MS, docking-based MM\\GBSA and MD simulation study","volume":"43","author":"Famuyiwa","year":"2023","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.neuron.2018.08.011","article-title":"Molecular Dynamics Simulation for All","volume":"99","author":"Hollingsworth","year":"2018","journal-title":"Neuron"},{"key":"ref_28","first-page":"289","article-title":"Immunohistochemical localization of group II phospholipase A2 in colonic mucosa of patients with inflammatory bowel disease","volume":"92","author":"Minami","year":"1997","journal-title":"Am. J. Gastroenterol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1039\/C4SC03398A","article-title":"The flexibility\u2013complementarity dichotomy in receptor\u2013ligand interactions","volume":"6","author":"Sun","year":"2015","journal-title":"Chem. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular Properties That Influence the Oral Bioavailability of Drug Candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1021\/cr990139w","article-title":"Interfacial Enzymology: The Secreted Phospholipase A2-Paradigm","volume":"101","author":"Berg","year":"2001","journal-title":"Chem. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1021\/acs.accounts.2c00497","article-title":"Membrane Association Allosterically Regulates Phospholipase A2 Enzymes and Their Specificity","volume":"55","author":"Mouchlis","year":"2022","journal-title":"Acc. Chem. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jconrel.2006.12.032","article-title":"A novel mechanism for oral controlled release of drugs by continuous degradation of a phospholipid prodrug along the intestine: In-vivo and in-vitro evaluation of an indomethacin\u2013lecithin conjugate","volume":"119","author":"Dahan","year":"2007","journal-title":"J. Control. Release"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejps.2017.06.022","article-title":"Phospholipid-drug conjugates as a novel oral drug targeting approach for the treatment of inflammatory bowel disease","volume":"108","author":"Dahan","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Markovic, M., Ben-Shabat, S., Manda, J.N., Abramov-Harpaz, K., Regev, C., Miller, Y., Aponick, A., Zimmermann, E.M., and Dahan, A. (2022). PLA2-triggered activation of cyclosporine-phospholipid prodrug as a drug targeting approach in inflammatory bowel disease therapy. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14030675"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1007\/s12010-024-05149-1","article-title":"Exploring benzo [d] thiazol-2-amine derivatives, synthesis, and molecular docking insights po-tential anticancer agents targeting HER Enzyme and DNA","volume":"197","author":"Hassan","year":"2025","journal-title":"Appl. Biochem. Biotechnol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/CAD.0000000000001749","article-title":"Exploring natural products for allosteric inhibition of glutathione peroxidase 4 in drug-resistant cancers via molecular docking and dynamics","volume":"36","author":"Yasir","year":"2025","journal-title":"Anti-Cancer Drugs"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers","volume":"1\u20132","author":"Abraham","year":"2015","journal-title":"SoftwareX"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1002\/prot.22711","article-title":"Improved side-chain torsion potentials for the Amber ff99SB protein force field","volume":"78","author":"Piana","year":"2010","journal-title":"Proteins"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/17\/3057\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:51:03Z","timestamp":1788529863000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/17\/3057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":39,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["molecules31173057"],"URL":"https:\/\/doi.org\/10.3390\/molecules31173057","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]}}}